How does lurbinectedin interact with CYP3A drugs?
Lurbinectedin is metabolized by CYP3A enzymes in the liver, so strong CYP3A inhibitors like ketoconazole, itraconazole, or ritonavir can raise its blood levels, increasing toxicity risks such as severe myelosuppression or hepatotoxicity. Strong CYP3A inducers like rifampin, carbamazepine, or phenytoin lower its levels, potentially reducing effectiveness. Avoid strong inhibitors during treatment and for 72 hours after; monitor closely with inducers and consider dose adjustments.[1][2]
What about interactions with other chemotherapy agents?
Lurbinectedin often pairs with drugs like doxorubicin or cisplatin in small cell lung cancer regimens. No major pharmacokinetic clashes occur, but additive bone marrow suppression heightens neutropenia and thrombocytopenia risks—dose reductions or delays may be needed. It also sensitizes cells to topoisomerase inhibitors, amplifying efficacy but myelotoxicity.[1][3]
Does lurbinectedin affect or get affected by anticoagulants or antiplatelets?
Its thrombocytopenia risk (common at grade 3-4) combines dangerously with warfarin, heparin, or aspirin, raising bleeding chances. Monitor INR closely with warfarin; use alternatives or prophylaxis if possible. No direct metabolic interaction, but clinical vigilance is key.[1][2]
Are there interactions with common supportive care drugs?
- Live vaccines: Avoid due to immunosuppression from lurbinectedin-induced neutropenia.
- PPIs or H2 blockers: Minimal impact, but monitor for reduced efficacy in acidic pH-dependent absorption scenarios.
- Alcohol: No specific data, but hepatotoxicity overlap advises moderation.[1][4]
What do patients need to watch for with OTC meds or supplements?
St. John's wort induces CYP3A, dropping lurbinectedin levels—stop it weeks before starting. Grapefruit juice acts as a moderate CYP3A inhibitor; avoid during and shortly after dosing. Herbal supplements like echinacea may alter immune response amid neutropenia.[2][4]
How is lurbinectedin monitored in polypharmacy?
Baseline liver function, CBC, and ECG are standard. Adjust doses for CrCL <30 mL/min or bilirubin >ULN. Drug interaction checkers like Lexicomp flag 200+ potential conflicts, mostly CYP3A-related. Consult oncology pharmacy for personalized regimens.[1][3]
[1]: Zepzelca (lurbinatedin) Prescribing Information, Jazz Pharmaceuticals, https://www.zepzelca.com/pdf/Zepzelca-PI.pdf
[2]: FDA Drug Label for Lurbinectedin, https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/213721s000lbl.pdf
[3]: Clinical Pharmacology Review, FDA Approval Package, https://www.accessdata.fda.gov/drugsatfdadocs/nda/2020/213721Orig1s000ClinPharmR.pdf
[4]: DrugPatentWatch.com - Lurbinectedin Interactions, https://www.drugpatentwatch.com/p/tradename/ZEPZELCA#interactions